Second NRF2 Degrader Enters Clinical Development: Nutshell Therapeutics' NTS231 Received FDA IND Clearance
Why now
Thesis: Early oncology asset enters clinic, value unproven
Catalyst to watch: Phase 1 safety and biomarker data
Main risk: Early-stage failure or dilution
Why it matters
FDA IND clearance advances an early-stage NRF2 degrader, but clinical and commercial outcomes remain years away.
Details
SHANGHAI, Sept. 25, 2026 /PRNewswire/ -- Nutshell Therapeutics (Shanghai) Co., Ltd. ("Nutshell Therapeutics"), an innovative biotech company focused on AI-driven allosteric drug discovery, announced FDA IND clearance for NTS231, a covalent allosteric molecular glue degrader of NRF2, to...
Related assets & topics
HealthcareSources
- prnewswire · 2026-09-25 12:00 UTC